Global TNF Inhibitors Market 2019-2023
About Tumor Necrosis Factor (TNF)
TNF is a cell signaling cytokine that is secreted by macrophages and plays a role in systemic inflammation, which is known to be the cause of various autoimmune diseases. TNF inhibitors are drugs that reverse the damage caused by these diseases.
Technavio’s analysts forecast the Global TNF Inhibitors Market to grow at a CAGR of 9.58% during the period 2019-2023.
Covered in this report
The report covers the present scenario and the growth prospects of the TNF inhibitors market. To calculate the market size, the report considers the revenue generated from the application of TNF inhibitors in healthcare across the globe.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report - Global TNF Inhibitors Market 2019-2023
Technavio recognizes the following companies as the key players in the global TNF inhibitors market: AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and UCB.
Commenting on the report, an analyst from Technavio’s team said: “One trend affecting this market is the growing number of strategic alliances. At the present, biotech companies dominate the research area for drugs for tumor necrosis factor as they out-license the molecules or technology platforms to the bigger pharmaceutical companies.”
According to the report, one driver influencing this market is the increasing prevalence of autoimmune disorders across the globe. The rising incidences of tumor necrosis factor cancer and growing prevalence of various autoimmune disorders such as RA, psoriasis, and Chron’s disease is expected to fuel the demand for TNF immunology across the period of forecast.
Further, the report states that one challenge affecting this market is the growing advent of biosimilars. Vendors are increasingly focused on the development of biosimilars, which is expected to hinder the growth of the TNF inhibitors market.
Johnson & Johnson